SPRB Spruce Biosciences, Inc.

9d ago, source: Seeking Alpha

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont ...

Spruce Biosciences Announces Upcoming Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting

2d ago, source: Yahoo Finance

April 22, 2024--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders ...

Spruce Biosciences (SPRB) Upgraded to Buy: Here's What You Should Know

28d ago, source: Hosted on MSN

Spruce Biosciences, Inc. (SPRB) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates ...

Spruce Biosciences gets grant for treatment of polycystic ovary syndrome with adrenal hyperandrogenism

2d ago, source: Pharmaceutical Technology

Treat PCOS-FAH effectively with Spruce Biosciences' patented method using a CRF1 antagonist. Say goodbye to hirsutism and infertility symptoms!

Spruce Biosciences Inc Ordinary Shares

6d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Spruce Biosciences Announces Upcoming Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting

2d ago, source: Stockhouse

s CAHmelia program evaluating tildacerfont in adult congenital adrenal hyperplasia (CAH), as an illustration of outcomes of current pediatric CAH disease management Spruce Biosciences, Inc. (Nasdaq: ...

Spruce Biosciences Inc.

1mon ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...